Related Experiment Video
Updated: Mar 13, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
CCN2 reduction mediates protective effects of BMP7 treatment in obstructive nephropathy
Lucas L Falke1, Jan Willem Leeuwis2, Karen M Lyons3
1Department of Pathology, Kidney Group, University Medical Centre Utrecht, H04.312, Heidelberglaan 100, 3584, CX, Utrecht, The Netherlands. lucasfalke@hotmail.com.
Abstract:
Treatment with rhBMP7 exerts profound protective effects in a wide variety of experimental models of renal disease. However, little is known about how these protective effects are mediated, and which cells in the kidney are targeted by exogenous rhBMP7 treatment. To determine if rhBMP7 increases glomerular and tubulointerstitial canonical BMP signaling, we performed Unilateral Ureteral Obstruction (UUO, a widely used obstructive nephropathy model) in mice reporting transcriptional activity downstream of canonical BMP signaling by the expression of GFP under the BMP Responsive Element of the Id1 promoter (BRE:gfp mice). We also analysed the impact of rhBMP7 treatment on severity of the UUO phenotype, on TGFβ signaling, and on expression of CCN2 (CTGF). Despite profound protective effects with respect to morphological damage, macrophage infiltration, and fibrosis, no significant difference in GFP-expression was observed upon rhBMP7 administration. Also TGFβ signalling was similar in rhBMP7 and vehicle treated mice, but CCN2 expression in obstructed kidneys was significantly reduced by rhBMP7 treatment. Of note, in heterozygous CCN2 mice (CCN2+/-) treatment with rhBMP7 did not (further) reduce the severity of kidney damage in the UUO-model. These data suggest that protection against obstructive nephropathy by exogenous rhBMP7 treatment relies primarily on non-canonical BMP signaling, and may be mediated in large part by downregulation of CCN2 expression.
Insights
Recombinant human bone morphogenetic protein 7 (rhBMP7) protects kidneys from damage by reducing CCN2 expression, suggesting a non-canonical signaling pathway mediates its therapeutic effects in obstructive nephropathy.
Area of Science:
- Nephrology
- Molecular Biology
- Regenerative Medicine
Background:
- Recombinant human bone morphogenetic protein 7 (rhBMP7) shows protective effects in various kidney disease models.
- The precise mechanisms and cellular targets of rhBMP7 in renal protection remain largely unknown.
Purpose of the Study:
- To investigate whether rhBMP7 modulates canonical Bone Morphogenetic Protein (BMP) signaling in the kidney.
- To determine the impact of rhBMP7 on the severity of obstructive nephropathy and associated molecular pathways.
Main Methods:
- Unilateral Ureteral Obstruction (UUO) model in mice (BRE:gfp) to track canonical BMP signaling.
- Administration of rhBMP7 or vehicle and assessment of renal damage, macrophage infiltration, fibrosis, TGFβ signaling, and CCN2 expression.
- Evaluation of rhBMP7 efficacy in heterozygous CCN2 knockout mice (CCN2+/-).
Main Results:
- rhBMP7 treatment significantly reduced morphological damage, macrophage infiltration, and fibrosis in the UUO model.
- No significant change in canonical BMP signaling (GFP expression) or TGFβ signaling was observed with rhBMP7 treatment.
- rhBMP7 significantly decreased CCN2 expression in obstructed kidneys, and this reduction was crucial for its protective effect in CCN2+/- mice.
Conclusions:
- rhBMP7-mediated protection against obstructive nephropathy is primarily mediated by non-canonical BMP signaling pathways.
- Downregulation of CCN2 expression by rhBMP7 is a key mechanism underlying its renoprotective effects.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

